HIV drug reduces GVHD in bone marrow transplant patients

August 2012
Infectious Disease News;Aug2012, Vol. 25 Issue 8, p8
The article discusses the research conducted by researchers at Abramson Cancer Center at the Hospital of the University of Pennsylvania on HIV drug reducing the graft-versus-host disease (GVHD) in bone marrow transplant patients.


Related Articles

  • Subnormal androgen levels in young female bone marrow transplant recipients with ovarian dysfunction, chronic GVHD and receiving glucocorticoid therapy. Saarinen-Pihkala, U. M.; Taskinen, M.; Wikström, A. M.; Dunkel, L.; Hovi, L. // Bone Marrow Transplantation;Mar2004, Vol. 33 Issue 5, p503 

    Summary:Ovarian function and sex hormone production with special focus on androgens (testosterone, androstenedione, dehydroepiandrosterone and its sulfate, DHEAS) was followed up during 1.5-20 (mean 9) years after bone marrow transplantation (BMT) in 24 female subjects aged 16-33 (mean 21) years...

  • Extracorporeal photopheresis in chronic graft-versus-host disease. Foss, FM; Gorgun, G; Miller, KB // Bone Marrow Transplantation;5/1/2002, Vol. 29 Issue 9, p719 

    Focuses on extracorporeal photopheresis (ECP), a novel therapeutic intervention which has demonstrated efficacy in patients with refractory acute and chronic graft-versus-host disease (cGVHD). Information on extracorporeal phototherapy; Mechanism of action of ECP; Effects of ECP on lymphocytes,...

  • Low transplant-related mortality in patients receiving unrelated donor marrow grafts for leukemia. Kalhs, P; Brugger, S; Reiter, E; Keil, F; Fischer, G; Schulenburg, A; Rabitsch, W; Rosenmayr, A; Dieckmann, K; Kurz, M; Schwarzinger, I; Volc-Platzer, B; Mannhalter, C; Lechner, K; Greinix, H T // Bone Marrow Transplantation;4/15/99, Vol. 23 Issue 8, p753 

    Transplantation with unrelated donor (UD) marrow has been shown to potentially cure patients with leukemia. Between January 1991 and April 1998, 54 patients with leukemia have received an UD BMT at our institution. Five patients received their UD BMT as a second transplant after a preceding...

  • Allogeneic bone marrow transplantation in the developing world: experience from a center in India. Chandy, M; Srivastava, A; Dennison, D; Mathews, V; George, B // Bone Marrow Transplantation;4/15/2001, Vol. 27 Issue 8, p785 

    We describe our experience of setting up an allogeneic BMT program at the Christian Medical College Hospital, Vellore over a period of 13 years, from October 1986 to December 1999. Two hundred and twenty-one transplants were performed during this period in 214 patients, with seven patients...

  • Blood: Mini-molecule governs severity of acute graft vs. host disease, study finds.  // Biomedical Market Newsletter;3/21/2012, Vol. 21, p1 

    The article offers information on a new research finding which led to the identification of new molecule which helps in controlling the severity of graft-versus- host disease in leukemia patients who have undergone bone marrow transplant.

  • Enlivex completes enrollment for GVHD in transplant.  // Worldwide Biotech;Sep2011, Vol. 23 Issue 9, p5 

    The article reports on biotechnology firm Enlivex Therapeutics' completion of enrollment for its Phase I/II clinical trials for the treatment of graft versus host disease (GVHD) in bone marrow transplant patients in Israel. The company is expecting to recruit about 12 patients in the next three...

  • Outcome following unrelated cord blood transplant in 136 patients with malignant and non-malignant diseases: a report from the Australian and New Zealand children's haematology and oncology group. Petterson, T. E.; Gabriel, M.; Tiedemann, K.; Teague, L.; Shaw, P. J.; Baker, D.; Bolton-Jones, R.; Tapp, H.; Oswald, C.; Vowels, M. R.; O'Brien, T. A. // Bone Marrow Transplantation;Feb2009, Vol. 43 Issue 3, p207 

    Unrelated umbilical cord blood (UCB) is an alternative stem cell source for paediatric patients lacking a matched related or unrelated marrow donor. We report the results of all paediatric unrelated UCB transplants performed in Australia and New Zealand over a 10-year period. A total of 135...

  • The Changing Face of Bone Marrow Transplant. Eisenberg, Seth // ONS Connect;Nov2012, Vol. 27 Issue 11, p10 

    The article offers information on improvement in bone marrow transplantation (BMT) technology in the U.S. It reflects that with a clear understanding of toxicities and the efficacy of supportive therapies, the risk of side effects has decreased. It informs that Myeloablative transplantation, the...

  • Ciclosporin/prednisone.  // Reactions Weekly;11/22/2008, Issue 1229, p10 

    The article describes the case of a 40-year-old man who developed oral proliferative verrucous leucoplakia (PVL) after receiving ciclosporin and prednisone after undergoing bone marrow transplantation (BMT). The patient had a history of subsequent graft versus host disease (GVHD). Time to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics